antimicrobial agent in soap
PreclinicalSmall molecule
antimicrobial agent in soap is one of 23 small molecule programs targeting Lymphedema. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Lymphedema
#DrugCompanyPhaseTrials
1Tocopherol
MM.D. Anderson Cancer Center
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Votrient
NovartisPhase 2
Fibrin Sealant
GGynecologic Oncology Group
Phase 3
IC-Green
CCHX Technologies Inc.
Phase 2
Inderal
WWyeth-Lederle Vaccines
Phase 2
Methylthioninium Chloride
PProvepharm SAS
Phase 2
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Trental
VValidus Pharmaceuticals
Phase 2
Hyperbaric Oxygen
IIntermountain Health Care, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for antimicrobial agent in soap. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details